{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-306222","form_type":"8-K","ticker":"DBVT","cik":"0001613780","company_name":"DBV Technologies S.A.","filed_at":"2026-07-16T21:02:04+00:00","discovered_at":"2026-07-16T21:04:00.268327+00:00","generated_at":"2026-07-16T21:04:07.772022+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"DBV Technologies H1 2026 net loss $98M; BLA submission for peanut patch delayed to Q3 2026","bullets":["Net loss of $98.0M for H1 2026 vs $69.0M for H1 2025; Q2 net loss $50.4M.","Cash and equivalents $174.9M as of June 30, 2026, funding into Q3 2027.","BLA submission for VIASKIN Peanut Patch (ages 4-7) now expected in Q3 2026, previously Q2.","R&D expenses $64.6M in H1 2026, up from $55.2M, driven by clinical trials and BLA prep.","SG&A expenses rose to $25.1M from $14.1M due to commercial infrastructure build."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-306222","json":"https://secwatch.observer/filing/0001193125-26-306222.json","markdown":"https://secwatch.observer/filing/0001193125-26-306222.md","text":"https://secwatch.observer/filing/0001193125-26-306222.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1613780/000119312526306222/0001193125-26-306222-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1613780/000119312526306222/d156695d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-16T21:04:07.772022+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}